Cargando…
Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date
BACKGROUND: In the past few years, new drugs made their appearance in the first-line setting of treatment for metastatic renal cell carcinoma (mRCC), and cabozantinib is one among them. The present systematic review aims to point out any evidence published to date about first-line treatment with cab...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6159801/ https://www.ncbi.nlm.nih.gov/pubmed/30288108 http://dx.doi.org/10.2147/CMAR.S160485 |